Abstract
Treatment of lung cancer is improving, also based on the identification of molecular characteristics of the tumor, of which some already constitute promising targets. One of the molecular characteristics thought to play an important role in lung cancer is DNA repair dysfunctionality. Deregulated expression of DNA repair proteins, such as PARP, has been studied in lung cancer as a possible biomarker and clinically useful target, but the literature remains relatively poor. Pharmacological inactivation of PARP has allowed the identification of a synthetic lethality with a second DNA repair protein such as BRCA1, but has also shown the potential to sensitize tumors to commonly used cytotoxic agents. The current manuscript reviews data regarding PARP in the context of DNA repair and its different pathways, as well as the clinical data generated until now with PARP inhibitors. A deeper understanding of the DNA damage response in lung malignancies, and particularly a clarification of the crosstalk between DNA repair functionality and genetic stability, is the key to optimize the development of PARP inhibitors in the setting of NSCLC.
Keywords: PARP1, lung cancer, synthetic lethality.
Current Pharmaceutical Design
Title:PARP Inhibitors: An Interesting Pathway also for Non-Small Cell Lung Cancer?
Volume: 20 Issue: 24
Author(s): Matteo Giaj Levra, Ken Andre Olaussen, Silvia Novello and Jean-Charles Soria
Affiliation:
Keywords: PARP1, lung cancer, synthetic lethality.
Abstract: Treatment of lung cancer is improving, also based on the identification of molecular characteristics of the tumor, of which some already constitute promising targets. One of the molecular characteristics thought to play an important role in lung cancer is DNA repair dysfunctionality. Deregulated expression of DNA repair proteins, such as PARP, has been studied in lung cancer as a possible biomarker and clinically useful target, but the literature remains relatively poor. Pharmacological inactivation of PARP has allowed the identification of a synthetic lethality with a second DNA repair protein such as BRCA1, but has also shown the potential to sensitize tumors to commonly used cytotoxic agents. The current manuscript reviews data regarding PARP in the context of DNA repair and its different pathways, as well as the clinical data generated until now with PARP inhibitors. A deeper understanding of the DNA damage response in lung malignancies, and particularly a clarification of the crosstalk between DNA repair functionality and genetic stability, is the key to optimize the development of PARP inhibitors in the setting of NSCLC.
Export Options
About this article
Cite this article as:
Levra Giaj Matteo, Olaussen Andre Ken, Novello Silvia and Soria Jean-Charles, PARP Inhibitors: An Interesting Pathway also for Non-Small Cell Lung Cancer?, Current Pharmaceutical Design 2014; 20 (24) . https://dx.doi.org/10.2174/13816128113196660765
DOI https://dx.doi.org/10.2174/13816128113196660765 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Application of Fungal Beta-glucans for the Treatment of Colon Cancer
Anti-Cancer Agents in Medicinal Chemistry Editorial
Reviews on Recent Clinical Trials Transition Metal-Based Prodrugs for Anticancer Drug Delivery
Current Medicinal Chemistry Reversing Aberrant Methylation Patterns in Cancer
Current Medicinal Chemistry The Use of SIFT-MS in Profiling the Faecal Volatile Metabolome in Horses with Colic: A Pilot Study
Current Analytical Chemistry Immune Therapy in Pancreatic Cancer: Now and the Future?
Reviews on Recent Clinical Trials Destabilizing Aneuploidy by Targeting Cell Cycle and Mitotic Checkpoint Proteins in Cancer Cells
Current Drug Targets Post-Transcriptional and Post-translational Regulation of Central Carbon Metabolic Enzymes in Cancer
Anti-Cancer Agents in Medicinal Chemistry Chemotherapy of Non-small Cell Lung Cancer in Elderly Patients
Current Medicinal Chemistry Tachykinins and their Receptors in Human Malignancies
Current Drug Targets Transport of Nucleoside Analogs Across the Plasma Membrane: A Clue to Understanding Drug-Induced Cytotoxicity
Current Drug Metabolism Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile
Current Cancer Drug Targets Recent Progress of Small Molecular VEGFR Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Nanotoxicity: The Toxicity Research Progress of Metal and Metal- Containing Nanoparticles
Mini-Reviews in Medicinal Chemistry Targeting Cancer Stem Cells and Non-Stem Cancer Cells: The Potential of Lipid- Based Nanoparticles
Current Pharmaceutical Design Proteoglycan Involvement in Inflammatory Diseases. New Developments in GAG-Based Therapies
Medicinal Chemistry Reviews - Online (Discontinued) Recent Advances for the Synthesis of Selenium-containing Small Molecules as Potent Antitumor Agents
Current Medicinal Chemistry A Combination of Two Antioxidants (An SOD Mimic and Ascorbate) Produces a Pro-Oxidative Effect Forcing Escherichia coli to Adapt Via Induction of oxyR Regulon
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs in Cancer Stem Cells: New Regulators of Stemness
Current Pharmaceutical Design Changes in and Impact of the Death Review Process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
Reviews on Recent Clinical Trials